Terashima I, Kohda K
Faculty of Pharmaceutical Sciences, Nagoya City University, Japan.
J Med Chem. 1998 Feb 12;41(4):503-8. doi: 10.1021/jm970363i.
A series of 4(6)-(benzyloxy)-2,6(4)-diamino-5-(nitro or nitroso)pyrimidine derivatives and analogues of which 4(6)-benzyloxy groups were replaced with a (2-, 3-, or 4-fluorobenzyl)oxy or (2-, 3-, or 4-pyridylmethyl)oxy group, was synthesized. The abilities of these compounds to inhibit human O6-alkylguanine-DNA alkyltransferase (AGAT) in vitro and to potentiate the cytotoxicity of 1-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-3-(2-chloroethyl) -3-nitrosourea (ACNU) toward HeLa S3 cells were evaluated. 2,4-Diamino-6-[(2-fluorobenzyl)oxy]-5-nitropyrimidine (3) and 2,4-diamino-5-nitro-6-(2-pyridylmethoxy)pyrimidine (6), whose ortho positions of the 6-substituent are modified, were much weaker in terms of these abilities than the corresponding meta- or para-modified compounds. These results are consistent with those of our previous study using a series of O6-benzylguanine derivatives. All 5-nitrosopyrimidine derivatives examined exerted both stronger AGAT-inhibition and ACNU-enhancement abilities than the corresponding 5-nitro derivatives. Among a variety of compounds that we have examined to date, 2,4-diamino-6-[(4-fluorobenzyl)oxy]-5-nitrosopyrimidine (10) exhibited the strongest ability to inhibit AGAT, and its magnitude was 2.5 and 50 times those of 4-(benzyloxy)-2,6-diamino-5-nitrosopyrimidine (9) and O6-benzylguanine (1), respectively. A strong positive correlation was observed between the ability to inhibit AGAT and to potentiate the cytotoxicity of ACNU. This strongly indicates that 4(6)-(benzyloxy)pyrimidine derivatives and their analogues potentiate ACNU cytotoxicity by inhibiting AGAT activity. To characterize the reactivity of test compounds, alkyl-transfer reactions were also carried out using the biomimetic alkyl-transfer system.
合成了一系列4(6)-(苄氧基)-2,6(4)-二氨基-5-(硝基或亚硝基)嘧啶衍生物及其类似物,其中4(6)-苄氧基被(2-、3-或4-氟苄基)氧基或(2-、3-或4-吡啶基甲基)氧基取代。评估了这些化合物在体外抑制人O6-烷基鸟嘌呤-DNA烷基转移酶(AGAT)的能力以及增强1-[(4-氨基-2-甲基-5-嘧啶基)甲基]-3-(2-氯乙基)-3-亚硝基脲(ACNU)对HeLa S3细胞细胞毒性的能力。6-取代基邻位被修饰的2,4-二氨基-6-[(2-氟苄基)氧基]-5-硝基嘧啶(3)和2,4-二氨基-5-硝基-6-(2-吡啶基甲氧基)嘧啶(6)在这些能力方面比相应的间位或对位修饰的化合物弱得多。这些结果与我们先前使用一系列O6-苄基鸟嘌呤衍生物的研究结果一致。所有检测的5-亚硝基嘧啶衍生物均表现出比相应的5-硝基衍生物更强的AGAT抑制能力和ACNU增强能力。在我们迄今为止检测的各种化合物中,2,4-二氨基-6-[(4-氟苄基)氧基]-5-亚硝基嘧啶(10)表现出最强的AGAT抑制能力,其强度分别是4-(苄氧基)-2,6-二氨基-5-亚硝基嘧啶(9)和O6-苄基鸟嘌呤(1)的2.5倍和50倍。在抑制AGAT的能力和增强ACNU细胞毒性的能力之间观察到强正相关。这有力地表明4(6)-(苄氧基)嘧啶衍生物及其类似物通过抑制AGAT活性增强ACNU细胞毒性。为了表征测试化合物的反应性,还使用仿生烷基转移系统进行了烷基转移反应。